MTAP and neoplasm: PRMT5 inhibitors might exert beneficial effects on tumor cytotoxicity (Kim et al, 2020) but also disrupt the tumor immunosurveillance (Strobl et al, 2020), possibly explaining why current PRMT5 inhibitors have no selectivity for MTAP‐loss tumors but instead are broadly anti‐proliferative.